APVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aptevo Therapeutics Inc (APVO) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 to invest. The company is facing significant financial challenges, including negative earnings, declining net income, and a reverse stock split, which are red flags for long-term stability. Despite a slight positive price movement and neutral trading sentiment, the lack of strong technical, financial, or sentiment-based catalysts suggests that holding off on investing in this stock is the better choice at this time.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 39.55, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 4.51, with resistance at 4.731 and support at 4.289, suggesting limited immediate upside potential.
The company has increased its cash and cash equivalents from $8.7 million to $21.6 million, providing operational runway through Q4 2026.
The company reported a FY GAAP EPS of -$87.27, highlighting significant financial struggles. A 1-for-18 reverse stock split was announced, which often signals financial distress. Additionally, revenue growth is stagnant, and net income and EPS have significantly declined year-over-year.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped by -6.56% YoY to -$5.89 million, and EPS fell by -100% YoY to -6.23. Gross margin remained at 0, indicating no profitability.
No analyst rating or price target changes available for review.
